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Purpose: The aim of the study was to assess the outcomes of severe retinopathy of prematurity 
(ROP) in zone I or posterior zone II treated with intravitreal ranibizumab (IVR) as monotherapy 
or combined treatment with laser photocoagulation.
Methods: This is a retrospective study analyzing clinical records of the included patients. 
Patients were divided into two groups: group 1 included patients who received only IVR 
treatment; and group 2 was subdivided into group 2A – including patients with IVR as initial 
treatment and complementary laser photocoagulation if retinal neovascularization or plus 
disease did not regress, and group 2B – including patients with initial laser photocoagulation 
and IVR as rescue therapy. Favorable outcomes were regression of the retinal neovasculariza-
tion and plus disease, meaning control of the disease. Unfavorable outcomes were progression 
to stages 4 and 5 of ROP.
Results: Fifty-seven eyes were included in the study. Mean birth weight and gestational age 
were 1,281±254 g and 29.5±2.1 weeks, respectively. Group 1 comprised of 16 eyes, with favor-
able outcomes in 14 eyes (87.5%). Group 2 comprised of 41 eyes, with favorable outcomes in 
29 eyes (70.7%), in a mean follow-up period of 12.8 months.
Conclusion: IVR was effective to treat severe cases of ROP as a primary or a combined treat-
ment. Forty-three of the 57 treated eyes (75.4%) achieved regression of ROP and favorable 
outcomes.
Keywords: aggressive posterior ROP, bevacizumab, prematurity, ranibizumab, retinopathy of 
prematurity, therapy, treatment, VEGF
Introduction
Aggressive posterior retinopathy of prematurity (AP-ROP) is an uncommon, severe, 
and rapidly progressing presentation of ROP.1
AP-ROP, when not promptly diagnosed and treated, can progress to retinal detach-
ment and blindness (stage 4 or 5 of ROP).2,3 AP-ROP, usually, occurs in more immature 
or sicker babies with extremely low birth weight (BW) as described in North America 
or Western European countries, as well as in bigger babies in Latin American, East 
European, or Asian countries.4
Laser photocoagulation remains the gold standard for the treatment of severe 
ROP in threshold or in type 1 prethreshold diseases according to the randomized 
trials Cryo-ROP and ETROP,5,6 but the anatomical and visual results of laser or cryo-
therapy in patients with severe ROP affecting zone I or posterior zone II are usually 
unfavorable.2,7–11
The role of vascular endothelial growth factor (VEGF) in the pathogenesis of 
ROP is well defined.12–15 Currently, bevacizumab is the most studied drug for ROP 
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treatment with encouraging results and very few ocular- or 
systemic-related complications.16–20 A prospective, random-
ized, multicenter trial (BEAT-ROP) assessed the efficacy 
of bevacizumab monotherapy in the treatment of premature 
patients with ROP in zone I or posterior zone II compared 
with conventional laser therapy. The study concluded that 
intravitreal bevacizumab monotherapy showed a significant 
benefit for zone I but not for zone II disease, as compared 
with laser photocoagulation.21
There are pharmacokinetic differences between bevaci-
zumab and ranibizumab, which may be important for safety 
in premature infants undergoing organogenesis. Despite 
the advantages related to ranibizumab when compared with 
bevacizumab for use in preterm infants with very low or with 
extremely low BW, there are a few studies on this drug for 
the treatment of severe cases of ROP.22,23
This study aims at analyzing the clinical records of 
patients with AP-ROP in zone I and posterior zone II and 
severe ROP 3 plus in posterior zone II treated with intrav-
itreal ranibizumab (IVR) as monotherapy or as a combined 
treatment and reports the results of the treatment.
Methods
study design
This is an institutional-based retrospective study conducted 
from July 2009 to June 2012 at the University Hospital of 
Maracaibo, Venezuela.
Patients
The study included all preterm infants with AP-ROP, defined 
according to the International Classification of ROP revisited 
from 2005,1 as well as preterm infants with severe ROP 3 plus 
who were treated with IVR in the Institution. There were no 
exclusion criteria.
Ophthalmological examination and 
interventions
All patients were evaluated preoperatively by binocular 
indirect ophthalmoscopy and by fundus retinal documenta-
tion with the RetCam® Imaging System (Clarity Medical 
Systems, Pleasanton, CA, USA). BW, gestational age (GA), 
classification of ROP in stages, zones, extension and severity, 
postconceptional age (PCA) at presentation, and PCA at 
treatment were registered.
Anti-VEGF therapy with IVR was performed in both 
eyes simultaneously. The injections of 0.25 mg (0.025 mL) 
of ranibizumab were injected at 1.5 mm posterior to the cor-
neal limbus. A disposable 1 mL syringe with a 30 G needle 
was used to treat all eyes. Preoperatively, Betadine was 
applied for cutaneous asepsis in all patients. All the injec-
tions were administered in the surgical room under topical 
anesthesia with proparacaine eye drops. After administering 
IVR injection, eye drops of antibiotic and steroids were used 
every 6 hours for 1 week.
Diode laser photocoagulation (Solitaire; Ellex Medical 
Pty Ltd®, Adelaide, SA, Australia), 0.15 seconds, and 
110 mW power, was applied in all quadrants (360°) from the 
posterior avascular retina to the ora serrata in a near confluent 
pattern (laser burns of less than one-half burn width apart). 
Laser photocoagulation was performed in the surgical room 
under general anesthesia or sedation.
Treatment criteria for initial IVR therapy were ROP 
location in zone I or posterior zone II and severity of ROP 
(severity of plus disease, pupillary rigidity and lack of 
pupillary dilation, or occurrence of vitreous hemorrhage not 
allowing laser photocoagulation). PCA at presentation was 
also considered for appropriate therapeutic approach.
Patients were included in one of the two groups: group 1 
included patients who received only one IVR injection; and 
group 2, subdivided into groups 2A and 2B, included patients 
who received combined treatment with only one IVR injec-
tion and laser photocoagulation (group 2A received IVR as 
initial treatment followed by laser photocoagulation after 
3 weeks if retinal neovascularization or plus disease did not 
regress; and group 2B, received initial laser photocoagulation 
and IVR as rescue therapy after failure of the laser treatment 
defined by the presence of persistent plus disease, progres-
sion of retinal neovascularization, or persistence of vitreous 
hemorrhage).
Outcomes evaluated and follow-up
Favorable outcomes were considered regression of the 
AP-ROP after treatment (regression of retinal neovascular-
ization and plus disease, meaning control of the disease), and 
unfavorable outcomes were progression to stages 4 and 5 of 
ROP. Follow-up evaluations were performed at 24 hours, 
48 hours, 1 week, 2 weeks, 1 month, 2 months, 3 months, 
6 months, 12 months, or more after treatment.
Ocular or systemic adverse effects 
registered
Short- and long-term (after 1-year follow-up) ocular adverse 
effects were registered as signs of intraocular inflammation or 
endophthalmitis, intraocular pressure elevation, and secondary 
cataract formation. Systemic adverse effects were closely 
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intravitreal ranibizumab for severe rOP
the Neonatal Intensive Care Unit, including continuous moni-
toring of blood pressure, oxygen saturation, and heart rates. 
Respiratory and cardiologic frequencies, and urinary or allergic 
side effects (rash or bronchospasm), were also monitored.
ethical aspects
The Research Ethics Committee of the University Hospital 
of Maracaibo approved the study protocol, and it was consis-
tent with the principles of the Declaration of Helsinki, 1995 
(revised in Edinburgh in 2000). The parents or their represen-
tatives have signed a consent form before the treatment.
Results
Twenty-nine patients (57 eyes) were included in the study. 
AP-ROP in zone I or in posterior zone II was diagnosed 
in 26 patients (51 eyes) and severe ROP 3 plus (threshold 
ROP) in posterior zone II was diagnosed in three patients (six 
eyes). Seventeen patients were female. Mean GA at birth was 
29.4±2.2 weeks (range: 25–33 weeks), BW was 1,272±255 g 
(range: 900–1,900 g), PCA at ROP diagnosis was 36±2.7 weeks, 
and PCA at treatment was 37.7±2.6 weeks (Table 1).
Group 1 comprised 16 eyes from eight patients (patients 
treated only once with IVR); and group 2 comprised 41 eyes 
from 21 patients (patients who received combined treatment 
with IVR and laser photocoagulation). In group 1, a total of 
14 eyes (seven patients) achieved favorable outcomes after 
the use of only one IVR injection in each eye (87.5%). It 
was remarkable that all the eyes that achieved favorable out-
comes in group 1 remained with peripheral avascular retina 
up to 6 months after treatment (Figure 1A–C). Two eyes of 
the same patient in group 1 had unfavorable outcomes with 
progression to ROP stage 4B in one eye and ROP stage 5 in 
the fellow eye after 3 weeks (Table 2).
In group 2, 29 eyes (15 patients) achieved favorable 
outcomes after combined treatment (70.7%). Twelve eyes 
in group 2 (29.3%) developed progression of ROP to stage 
4 or 5 with unfavorable outcomes, after a mean of 6 weeks. 
Thirteen eyes (group 2A) received IVR as initial treatment, 
and after plus disease reactivation, they were treated with 
laser photocoagulation in zones II and III, but not in zone I. 
There were no unfavorable outcomes in patients included 
in group 2A. Twenty-eight eyes (group 2B) received laser 
photocoagulation as initial treatment and IVR was used 
after laser failure. Twelve eyes of group 2B had unfavorable 
outcomes (42.8%; Table 2).
The mean follow-up period was 12.8 months. No short- or 
long-term ocular or systemic adverse effects were registered 
in this cohort of 29 treated patients.
Discussion
The characteristic features of AP-ROP are its posterior 
location (zone I or posterior zone II), prominence of plus 
disease with flat neovascularization, retinal hemorrhages at 
the junction between the vascularized and avascular retina, 
intraretinal shunting without ridge tissue formation, and ill-
defined nature of the retinopathy without progression through 
classic stages 1–3 of ROP.1–3
Bevacizumab is a full-length antibody that contains the 
fraction of neonatal Fc (FcRn) receptor while ranibizumab 
does not contain this particular factor.24 Earlier studies 
have reported that the trans-retinal penetration varies with 
the molecular weight of the diffusing agent and the blood–
brain barrier contains the FcRn immunoglobulin G (IgG) 
receptor/transporter that is necessary to permit the passage 
of the intravitreal drug through the retinal barrier achiev-
ing extraocular penetration.24,25 The authors suggest that 
bevacizumab escapes from the vitreous into the systemic 
circulation and reduces the systemic VEGF concentrations 
in ROP infants.26,27 Ranibizumab does not contain the frac-
tion of FcRn, and it is supposed that IVR does not achieve 
significant extraocular concentration after use. Ranibizumab, 
as a smaller molecule, represents greater activity with less 
half-life in the vitreous as compared with the bevacizumab 
(2.88 days versus 4.32 days, respectively).28,29
This study reports a cohort of 29 preterm infants with 
mean BW and GA of 1,272±255 g (range: 900–1,900 g) 
and 29.4±2.2 weeks (range: 25–33 weeks), respectively. 
These characteristics of BW and GA are representative 
for cohorts of patients originated from the Latin American 
countries, which comprised bigger and more mature babies 





GA, weeks  
(mean ± SD)
BW, grams  
(mean ± SD)
PCA at treatment,  
weeks (mean ± SD)
group 1 iVr 8 16 28.1±3.8 1,329±328 36.6±1.9
group 2 iVr + laser 21 41 29.9±2.0 1,214±229 38.2±3.0
Total 29 57 29.4±2.2 1,272±255 37.7±2.6
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developing severe ROP than the cohorts of patients related 
in USA, Canada, or Western European countries, usually 
restricted to smaller and more immature babies developing 
severe ROP. In developing countries, missed ROP screen-
ing, lack of awareness of risk factors for ROP, and unmoni-
tored supplemental oxygen in many less equipped Neonatal 
Intensive Care Units are some of the causative factors for 
this difference.4,30,31 The optimal time for treatment is very 
important for ROP outcomes. Most of the patients included in 
the study were transferred from different institutions for ROP 
treatment; mean PCA at ROP diagnosis was 36±2.7 weeks 
and at treatment was 37.7±2.6 weeks. However, PCA at treat-
ment may influence outcomes.32 Group 1 underwent treatment 
at a mean PCA of 36.6 weeks and group 2 at 38.2 weeks. 
It appears that better results observed in group 1 might be 
influenced by this variable.
Laser therapy is effective for the treatment of severe 
forms of ROP, as prethreshold type 1 ROP, threshold ROP, 
and in ∼50% of the patients treated with AP-ROP,2,4,33 but 
laser always damages the peripheral retina. Anti-VEGF 
therapy does not produce peripheral retinal ablation and may 
help to maintain a normal retinal function.34 However, there 
are many concerns with the anti-VEGF therapy in such at-risk 
population regarding the possibility of long-term systemic 
complications because organogenesis is occurring during the 
same period when ROP should be treated.35,36
Serum concentrations of bevacizumab and VEGF were 
reported by Sato et al in infants who were treated with 
Figure 1 image before iVr monotherapy (A); 6 days after iVr monotherapy (B); and after 6 months of iVr monotherapy (C).
Abbreviation: iVr, intravitreal ranibizumab.
Table 2 results of treatment according to groups
Number of included eyes Favorable outcomes, n eyes (%) Unfavorable outcomes, n eyes (%)
group 1 iVr 16 14 (87.5%) 2 (12.5%)
group 2 iVr + laser
group 2 (a + B) 41 29 (70.7%) 12 (29.3%)
group 2a: initial iVr 13 13 (100%) 0 (0%)
group 2B: initial laser 28 16 (57.1%) 12 (42.8%)
Total 57 43 (75.4%) 14 (24.6%)
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intravitreal ranibizumab for severe rOP
0.5–1.0 mg of intravitreal bevacizumab for severe ROP. 
The authors suggested that bevacizumab escapes from the 
vitreous into the systemic circulation and reduces the VEGF 
concentrations in ROP infants.27 Ranibizumab is a different 
molecule, and it is supposed that this drug does not achieve 
significant extraocular concentration after the intravitreal 
use. In animal models, no ranibizumab was detected in 
the serum or on the fellow untreated eye, whereas small 
amounts of intravitreal bevacizumab have been detected in 
the serum and in the fellow uninjected eye.28,29 Ranibizumab, 
as a smaller molecule, represents greater activity with less 
half-life in the vitreous as compared with bevacizumab.28,29 
In adults, Carneiro et al reported similar efficacy of ranibi-
zumab and bevacizumab but with the advantage that it does 
not alter systemic VEGF levels.37 This is a very important 
point to be considered for the use of IVR in preterm babies 
under organogenesis period, but despite of these apparent 
advantages on pharmacokinetics related to ranibizumab, 
when compared with bevacizumab for the use in premature 
infants, this drug has only recently been used for the treat-
ment of severe presentations of ROP.22,23,38
In this study, IVR injections were used in 57 eyes and a 
regression of plus disease and retinal neovascularization was 
registered in 43 of the treated eyes. This represents 75.4% of 
favorable outcomes. Fourteen eyes had unfavorable evolu-
tion after treatment and progressed to stage 4B or 5 of ROP. 
Sixteen eyes were included in group 1 and 14 eyes achieved 
favorable outcomes (87.5%). It was remarkable that all eyes 
that achieved favorable outcomes in the IVR group remained 
with avascular peripheral retina up to 6 months after treat-
ment. These findings are according to previous reports 
on the use of bevacizumab.34 Group 2 comprised 41 eyes. 
Twenty-nine eyes achieved favorable outcomes (70.7%) 
in the entire group. Thirteen eyes (group 2A) received IVR 
as initial treatment and, after failure, received rescue laser 
photocoagulation in zones II and III, but not in zone I. 
ROP reactivation after treatment with IVR was reported by 
Wong et al.39 The shorted life of ranibizumab justified it. 
Krohne et al determined an aqueous half-life of 7.19 days 
in humans.40 Zhou et al reported that IVR reduce plasma 
VEGF levels only for 1 week.41 Twenty-eight eyes (group 2B) 
received laser photocoagulation by initial treatment and IVR 
was used after laser failure. It is important to mention that 
in group 2, better favorable outcomes were observed when 
patients received initial IVR injection and complementary 
laser treatment (group 2A – 100% of favorable outcomes) 
than in patients who were initially treated by laser photoco-
agulation followed by IVR (group 2B – 57.1% of favorable 
outcomes).
This study showed no complications related to the proce-
dure itself, that is, neither systemic side effects nor adverse 
events. Delayed retinal vascularization after IVR injection was 
observed, as described in earlier studies, and thus demanding 
longer ophthalmological follow-up of those patients.39–44
Further studies are necessary to evaluate safety and effi-
cacy of new anti-VEGF drugs to minimize potential systemic 
long-term consequences and to evaluate retinal functions in 
preterm babies.
Conclusion
We reported favorable outcomes after the use of IVR, as 
monotherapy or combined with laser photocoagulation, to 
treat severe cases of AP-ROP in zone I and posterior zone II, 
as well as in severe ROP 3 plus in posterior zone II. Final 
favorable outcomes with regression of retinal neovascular-
ization and control of the ROP were obtained in 43 eyes of 
the 57 treated eyes (75.4%). During the follow-up period, 
no ocular or systemic complications were registered in our 
patients. The shorter half-life of ranibizumab can be associ-
ated with the higher chance of reactivations or persistent 
avascular peripheral retina.
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